PUBLISHER: FirstWord Group | PRODUCT CODE: 1564675
PUBLISHER: FirstWord Group | PRODUCT CODE: 1564675
Colorectal Cancer - KOL Insight
This report provides an in-depth analysis of the latest trends and developments in colorectal cancer (CRC) treatment, based on insights from 12 leading key opinion leaders (KOLs) in North America and Europe. The report covers current therapies, including oral multikinase inhibitors, HER-2 inhibitors, and immunotherapies, and evaluates their efficacy and tolerability. It also explores promising pipeline products, the potential impact of ongoing clinical trials, and future treatment pathways. Additionally, the report addresses the challenges and opportunities in the CRC market, offering valuable perspectives for pharmaceutical professionals.
Key brands covered in this report:
|
|
Key questions answered:
- How are currently approved therapies for CRC perceived in terms of efficacy and tolerability?
- Which drug class has the greatest potential to impact prescribing trends?
- Which pipeline products are the most promising, and how will they affect the market?
- Which clinical trials have the potential to impact future CRC treatment protocols?
- How will the diagnosis of mCRC evolve in the future?
- What are the most promising future treatments for CRC?
- What are the major challenges and opportunities in the mCRC market?
Companies:
Amgen, Roche, GSK, AstraZeneca, Merck, Merck & Co., Bristol Myers Squibb, Jazz Pharmaceuticals, Genentech, Gilead Sciences, Daiichi Sankyo, Bayer, Array BioPharma, Leap Therapeutics, Exelixis, Mirati, Seagen, Vaccinogen, Arcus Biosciences, Ono Pharmaceutical, Innovative Cellular Therapeutics, Faron Pharmaceuticals, Agenus, Gritstone bio, Hutchmed, Cardiff Oncology, Akeso Biopharma, Carina Biotech, Redx Pharma, Revolution Medicines.
Table of Contents
Executive summary
Research objectives
Marketed products
Oral multikinase inhibitors
- Key insights summary
- Stivarga (regorafenib; Bayer)
- Fruzaqla (fruquintinib; HUTCHMED)
HER-2 inhibitors
- Key insights summary
- Tukysa (tucatinib; Array BioPharma/Merck & Co./Seagen)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
PD-1/CTLA-4 immunotherapies
- Key insights summary
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; BMS/Ono)
- Yervoy (ipilimumab; BMS)
KRAS inhibitors
- Key insights summary
- Krazati (adagrasib; BMS/Mirati Therapeutics)
Late-stage pipeline drugs
Oral multikinase inhibitors
- Key insights summary
- Zanzalintinib (Exelixis)
HER-2 inhibitors
- Key insights summary
- Zanidatamab (Jazz Pharmaceuticals)
KRAS inhibitors
- Key insights summary
- Lumakras (sotorasib; Amgen)
- GDC-6036 (divarasib; Roche)
- Pan-KRAS inhibitors (RMC-98051 and RMC-6236; Revolution Medicines)
Cancer vaccines
- Key insights summary
- OncoVAX (Vaccinogen)
- GRANITE (Gritstone bio)
Checkpoint inhibitors
- Jemperli (dostarlimab; GSK)
- Key insights summary
- Bavencio (avelumab; Merck KGaA)
- Key insights summary
- Tecentriq (atezolizumab; Roche/Genentech)
- Key insights summary
- LAG-3/PD-1 combinations
- Key insights summary
- Nivolumab + relatlimab (Bristol Myers Squibb)
- Pembrolizumab + favezelimab (MK-4280A; Merck & Co.)
- Next-generation CTLA-4/PD-1 combinations
- Botensilimab/balstilimab (Agenus)
- Key insights summary
- Novel bispecific and trispecific mAbs
- Cadonilimab (Akeso Biopharma)
- Key insights summary
Mid/early-stage pipeline
- ADCs and other modalities
- Key insights summary
- CCR8 inhibitors
- TROP2 CAR engineered IL-15- transduced cord blood (CB)-NK cells
- Anti-claudin18.2 mAbs
- Anti-CEACAM5 ADCs
- Wnt signalling inhibitors
- Key insights summary
- Sirexatamab (DKN 01; Leap Therapeutics)
- Zamaporvint (RXC004; Redx Pharma)
- TIGIT inhibitors
- Key insights summary
- Tiragolumab (Genentech)
- Domvanalimab (Gilead)
- Vibostolimab (Merck)
- Dual antagonist of A2a/A2b receptors
- Key insights summary
- Etrumadenant (Arcus Biosciences)
- Polo-like-kinase 1 inhibitor
- Key insights summary
- Onvansertib (Cardiff Oncology)
- CLEVER-1 inhibitors
- Key insights summary
- Bexmarilimab (Faron Pharmaceuticals)
- CAR-Ts Therapies
- Key insights summary
- CNA3103 (Carina Biotech)
- GCC19CART (Innovative Cellular Therapeutics)
Future outlook
- Key insights summary
- In the future, oncologists anticipate better molecular characterisation of CRC to tailor treatment strategies
Appendix
- KOL details
